Compare ULBI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULBI | CMPX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.9M | 752.4M |
| IPO Year | 1992 | N/A |
| Metric | ULBI | CMPX |
|---|---|---|
| Price | $5.84 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.44 |
| AVG Volume (30 Days) | 42.8K | ★ 1.8M |
| Earning Date | 11-18-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $186,530,000.00 | N/A |
| Revenue This Year | $31.30 | N/A |
| Revenue Next Year | $6.24 | N/A |
| P/E Ratio | $58.88 | ★ N/A |
| Revenue Growth | ★ 12.94 | N/A |
| 52 Week Low | $4.07 | $1.33 |
| 52 Week High | $9.52 | $5.86 |
| Indicator | ULBI | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 50.88 |
| Support Level | $5.41 | $4.83 |
| Resistance Level | $6.25 | $5.32 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 51.76 | 20.87 |
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.